PFS2 and adjustment of overall survival (OS) for subsequent anticancer therapy in patients (pts) with primary advanced or recurrent endometrial cancer (pA/rEC) treated with dostarlimab plus chemotherapy or chemotherapy alone in the ENGOT-EN3-NSGO/GOG-3031/RUBY trial
Slomovitz BM, Raaschou-Jensen N, Coleman RL, Gilbert L, Powell MA, Cibula D, Ghamande S, Zavallone L, Mendivil AA, Ataseven B, Black D, et al. (2023)
In: Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023. Annals of Oncology , 34(Suppl. 2). Amsterdam: Elsevier: S514-S515.
Kurzbeitrag Konferenz / Poster
| Veröffentlicht | Englisch
Download
Es wurden keine Dateien hochgeladen. Nur Publikationsnachweis!
Autor*in
Slomovitz, B. M.;
Raaschou-Jensen, N.;
Coleman, R. L.;
Gilbert, L.;
Powell, M. A.;
Cibula, D.;
Ghamande, S.;
Zavallone, L.;
Mendivil, A. A.;
Ataseven, BeyhanUniBi;
Black, D.;
Wymenga, M.
Alle
Alle
Einrichtung
Erscheinungsjahr
2023
Titel des Konferenzbandes
Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023
Serien- oder Zeitschriftentitel
Annals of Oncology
Band
34
Ausgabe
Suppl. 2
Seite(n)
S514-S515
Konferenz
Annual Meeting of the European-Society-for-Medical-Oncology (ESMO)
Konferenzort
Barcelona, SPAIN
Konferenzdatum
2023-12-20 – 2023-1024
ISSN
0923-7534
eISSN
1569-8041
Page URI
https://pub.uni-bielefeld.de/record/2985382
Zitieren
Slomovitz BM, Raaschou-Jensen N, Coleman RL, et al. PFS2 and adjustment of overall survival (OS) for subsequent anticancer therapy in patients (pts) with primary advanced or recurrent endometrial cancer (pA/rEC) treated with dostarlimab plus chemotherapy or chemotherapy alone in the ENGOT-EN3-NSGO/GOG-3031/RUBY trial. In: Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023. Annals of Oncology . Vol 34. Amsterdam: Elsevier; 2023: S514-S515.
Slomovitz, B. M., Raaschou-Jensen, N., Coleman, R. L., Gilbert, L., Powell, M. A., Cibula, D., Ghamande, S., et al. (2023). PFS2 and adjustment of overall survival (OS) for subsequent anticancer therapy in patients (pts) with primary advanced or recurrent endometrial cancer (pA/rEC) treated with dostarlimab plus chemotherapy or chemotherapy alone in the ENGOT-EN3-NSGO/GOG-3031/RUBY trial. Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023, Annals of Oncology , 34, S514-S515. Amsterdam: Elsevier. https://doi.org/10.1016/j.annonc.2023.09.1929
Slomovitz, B. M., Raaschou-Jensen, N., Coleman, R. L., Gilbert, L., Powell, M. A., Cibula, D., Ghamande, S., et al. 2023. “PFS2 and adjustment of overall survival (OS) for subsequent anticancer therapy in patients (pts) with primary advanced or recurrent endometrial cancer (pA/rEC) treated with dostarlimab plus chemotherapy or chemotherapy alone in the ENGOT-EN3-NSGO/GOG-3031/RUBY trial”. In Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023, 34:S514-S515. Annals of Oncology . Amsterdam: Elsevier.
Slomovitz, B. M., Raaschou-Jensen, N., Coleman, R. L., Gilbert, L., Powell, M. A., Cibula, D., Ghamande, S., Zavallone, L., Mendivil, A. A., Ataseven, B., et al. (2023). “PFS2 and adjustment of overall survival (OS) for subsequent anticancer therapy in patients (pts) with primary advanced or recurrent endometrial cancer (pA/rEC) treated with dostarlimab plus chemotherapy or chemotherapy alone in the ENGOT-EN3-NSGO/GOG-3031/RUBY trial” in Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023 Annals of Oncology , vol. 34, (Amsterdam: Elsevier), S514-S515.
Slomovitz, B.M., et al., 2023. PFS2 and adjustment of overall survival (OS) for subsequent anticancer therapy in patients (pts) with primary advanced or recurrent endometrial cancer (pA/rEC) treated with dostarlimab plus chemotherapy or chemotherapy alone in the ENGOT-EN3-NSGO/GOG-3031/RUBY trial. In Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023. Annals of Oncology . no.34 Amsterdam: Elsevier, pp. S514-S515.
B.M. Slomovitz, et al., “PFS2 and adjustment of overall survival (OS) for subsequent anticancer therapy in patients (pts) with primary advanced or recurrent endometrial cancer (pA/rEC) treated with dostarlimab plus chemotherapy or chemotherapy alone in the ENGOT-EN3-NSGO/GOG-3031/RUBY trial”, Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023, Annals of Oncology , vol. 34, Amsterdam: Elsevier, 2023, pp.S514-S515.
Slomovitz, B.M., Raaschou-Jensen, N., Coleman, R.L., Gilbert, L., Powell, M.A., Cibula, D., Ghamande, S., Zavallone, L., Mendivil, A.A., Ataseven, B., Black, D., Wymenga, M., Billingsley, C., Willmott, L.J., McCourt, C., Podzielinski, I., Doehring, O., Garside, J., Herzog, T.J., Mirza, M.R.: PFS2 and adjustment of overall survival (OS) for subsequent anticancer therapy in patients (pts) with primary advanced or recurrent endometrial cancer (pA/rEC) treated with dostarlimab plus chemotherapy or chemotherapy alone in the ENGOT-EN3-NSGO/GOG-3031/RUBY trial. Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023. Annals of Oncology . 34, p. S514-S515. Elsevier, Amsterdam (2023).
Slomovitz, B. M., Raaschou-Jensen, N., Coleman, R. L., Gilbert, L., Powell, M. A., Cibula, D., Ghamande, S., Zavallone, L., Mendivil, A. A., Ataseven, Beyhan, Black, D., Wymenga, M., Billingsley, C., Willmott, L. J., McCourt, C., Podzielinski, I., Doehring, O., Garside, J., Herzog, T. J., and Mirza, M. R. “PFS2 and adjustment of overall survival (OS) for subsequent anticancer therapy in patients (pts) with primary advanced or recurrent endometrial cancer (pA/rEC) treated with dostarlimab plus chemotherapy or chemotherapy alone in the ENGOT-EN3-NSGO/GOG-3031/RUBY trial”. Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023. Amsterdam: Elsevier, 2023.Vol. 34. Annals of Oncology . S514-S515.
Export
Markieren/ Markierung löschen
Markierte Publikationen
Web of Science
Dieser Datensatz im Web of Science®Suchen in
Google Scholar